Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants

Gerard Short, Michael Zoerer, Emma Hilton, Taina Gomes, Jan Ohrstrom, Bo Persson, Daniël Verhoef, Pieter H. Reitsma

Blood (2024) 144 (Supplement 1): 2624.

https://doi.org/10.1182/blood-2024-201421

Published: 2024

Journal Articles

Vmx-C001 Prevents Rivaroxaban-Induced Bleeding in a Liver Injury Model in Cynomolgus Monkeys

Daniël Verhoef, Viola J.F. Strijbis, Taina Gomes, Jan Ohrstrom, Gerard Short, Michael Zoerer, Pieter H. Reitsma

Blood (2024) 144 (Supplement 1): 1195.

https://doi.org/10.1182/blood-2024-205141

Published: 2024

Journal Articles

Human Prothrombin Variants with Modifications in the Active Site S4 Subpocket Demonstrate Resistance to Dabigatran

Viola J.F. Strijbis, Ka Lei Cheung, Tessa A. Rutten, Pieter H. Reitsma, Daniel Verhoef, Mettine H.A. Bos

Blood (2021) 138 (Supplement 1): 439.

https://doi.org/10.1182/blood-2021-150212

Published: 2021

Journal Articles

A Novel Lysine to Arginine Substitution at Position 301 Enhances Activity of Factor IX

Daniel Verhoef, Jonathan H. Foley, Andrew Goodale, Emma Macrae, Jenny McIntosh, PhD, Romuald Corbau, PhD, Keith Gomez, Anne Riddell, Amit C Nathwani, MD PhD

Blood (2018) 132 (Supplement 1): 3772.

https://doi.org/10.1182/blood-2018-99-112832

Published: 2018

Journal Articles

Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors

Mark Schreuder, MD, Daniel Verhoef, MSc, Ka Lei Cheung, Koen Visscher, MSc, Daan Geerke, PhD, Pieter H. Reitsma, PhD, Mettine H.A. Bos, PhD

Blood (2017) 130 (Supplement 1): 363.

https://doi.org/10.1182/blood.V130.Suppl_1.363.363

Published: 2017

Journal Articles

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Daniël Verhoef, Mark Schreuder, Ka Lei Cheung, Pieter H. Reitsma, Mettine H.A. Bos, PhD

Blood (2015) 126 (23): 126.

https://doi.org/10.1182/blood.V126.23.126.126

Published: 2015

NARROW

Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants

Vmx-C001 Prevents Rivaroxaban-Induced Bleeding in a Liver Injury Model in Cynomolgus Monkeys

Human Prothrombin Variants with Modifications in the Active Site S4 Subpocket Demonstrate Resistance to Dabigatran

A Novel Lysine to Arginine Substitution at Position 301 Enhances Activity of Factor IX

Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants

Vmx-C001 Prevents Rivaroxaban-Induced Bleeding in a Liver Injury Model in Cynomolgus Monkeys

Human Prothrombin Variants with Modifications in the Active Site S4 Subpocket Demonstrate Resistance to Dabigatran

A Novel Lysine to Arginine Substitution at Position 301 Enhances Activity of Factor IX

Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only